KLRA — Kailera Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2096997 ·
Last close
$20.68
Market Cap
$2.68B
52W High
$28.23
52W Low
$18.50
ADV30
957,385
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -84,660,000 | -78,865,000 | 624,756,000 | 111,826,000 | 1,056,844,000 |
| Mar 2025 | 0 | — | -20,458,000 | -17,983,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-86,511,000
Investing CF
$-31,591,000
Financing CF
$-2,980,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.82
As of
2026-05-27
Balance + Analyst (yfinance extras)
Retained Earnings
$-447,533,000
Inventory
—
Receivables
$3,208,000
ST Investments
$407,348,000
EBIT TTM
$-105,118,000
Pretax Income TTM
$-96,848,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -158,340,000 | -148,955,000 | 692,294,000 | 1,048,752,000 | — | -120,210,000 |
| Dec 2024 | — | — | — | 178,445,000 | 397,217,000 | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.10
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMNM | Immunome Inc. | $2.64B | $23.35 | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.81B | $48.46 | — |
| TRVI | Trevi Therapeutics, Inc. | $2.53B | $17.84 | — |
| SLS | SELLAS Life Sciences Group, Inc. | $2.51B | $12.76 | — |
| MLYS | Mineralys Therapeutics, Inc. | $2.50B | $28.38 | — |
News headlines (Yahoo Finance, 1h cache)
Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential
2026-07-10 13:58 · Yahoo
Kailera weight loss pill trial results: Nausea sinks stock
2026-07-08 14:10 · Yahoo
Eli Lilly's Market Cap Balloons Again On This IPO's Setback
2026-07-07 20:09 · Yahoo
Update: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fall
2026-07-07 18:49 · Yahoo
Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial
2026-07-07 12:08 · Yahoo
Kailera says obesity pill succeeds in late-stage trial in China
2026-07-07 11:59 · Yahoo
Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
2026-07-07 11:00 · Yahoo
Pfizer's CEO Says His Company Has a "Very Big Balance Sheet" to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma Giant.
2026-07-02 21:20 · Yahoo
Kailera Therapeutics (KLRA) Stock Looks Overvalued Despite Its 20% Slump
2026-07-02 16:12 · Yahoo
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
2026-06-29 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.